

FEB 1 7 2004

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCETRANSMITTAL  
FORM

(to be used for all correspondence after initial filing)

	Application Number	10/649,495	
	Filing Date	08/27/2003	
	First Named Inventor	Wu et al.	
	Art Unit	1625	
	Examiner Name	To Be Assigned	
Total Number of Pages in This Submission	5	Attorney Docket Number	CN01622

## ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		


References (10); Post Card

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	William Y. Lee, Reg. No. 46, 100
Signature	
Date	02/12/2004

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	William Y. Lee, Reg. No. 46, 100
Signature	
Date	02/12/2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT CASE: CN01622

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wu et al. : Examiner: To Be Assigned  
For Patent: Selective D1/D5 Receptor : Date: February 12, 2004  
Antagonists for the Treatment of Obesity :  
and CNS Disorders : Group Art Unit: 1625  
Serial No.: 10/649,495 :  
Filed: 08/27/2003 : X

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to Rule 56, it is requested that the documents listed on the accompanying PTO-1449 Form be considered and made of record in the above-identified patent application. Copy(ies) of these references  are attached  were filed in related application U.S. Serial No(s) \_\_\_\_\_ filed \_\_\_\_\_, respectively.

(b) No fee is believed due because:

- This Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- This Information Disclosure Statement is being concurrently filed with the above-identified application.
- This Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
- This Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

(c)  This Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and

- Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; or

The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.

- (d)  This Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; and
- The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.

The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 19-0365, Patent Case No. CN01622. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,

SCHERING-PLOUGH CORPORATION

Dated: 02/12/2004  
SCHERING-PLOUGH CORPORATION  
Patent Department, K-6-1, 1990  
2000 Galloping Hill Road  
Kenilworth, NJ 07033-0530  
Facsimile No.: (908) 298-5388

By:

  
\_\_\_\_\_  
Name: William Y. Lee  
Reg. No.: 46,100  
**Attorney of Record**  
Telephone No.: (908) 298-2161

FEB 17 2004

Sheet \_\_\_ of \_\_\_



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.:  
**CN01622**APPLICATION NO.:  
**10/649,495**APPLICANT:  
**Wu et al.**FILING DATE:  
**08/27/2003**GROUP:  
**1625**

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL	EP0351733A	01/24/90	EUROPE			
AM	EP0230270A	07/29/87	EUROPE			
AN	WO 03/006466	01/23/03	PCT			
AO						
AP						

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AQ	Hollander, et al., J. Clin. Psychiatry 57 (Suppl. 8), pp.3-6 (1996)
AR	Phillips, J. Clin. Psychiatry 57 (Suppl. 8), pp 61-64 (1996)
AS	Merck Index, 15 <sup>th</sup> Edition (1987), page 2280-2281
AT	Christenson, Gary; O'Sullivan Richard, Trichotillomania: Rational treatment options, CNS Drugs (1996), 6(1), 23-34;
AU	Tukel R; Keser V; Karali NT; Olgun TO; Calikusu C., Comparison of clinical characteristics in trichotillomania and obsessive-compulsive disorder, Journal of Anxiety Disorders (2001 Sept-Oct), 15(5), 433-441;
AV	Du Toit P L; van Kradenburg J; Niehaus D J; Stein D J, Characteristics and phenomenology of hair-pulling: an exploration of subtypes, Comprehensive Psychiatry (2001 May-Jun), 42(3), 247-256.
AW	International Search Report for PCT/US 03/26878 (CN01622), international filing date 08/27/2003, 5 Pages

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.